References
To the Editor:
Dr. Frankel has chided us for not including more information and references on percutaneous pericardial drainage and chemical sclerosis (PPDS). The reality of limitations on word count and citations required to keep journal articles of reasonable length make it impossible for authors to satisfy all readers. We did include the largest published series of pericardial drainage cases from the Mayo group, 1 as well as three other references, and have discussed the relative merits of these techniques in more detail elsewhere. 2 Although Dr. Frankel believes that PPDS is "just as effective and obviously less morbid" as well as less expensive than surgical techniques, there are only 140 patients in the three series he cites. [3] [4] [5] Even in experienced hands, guided by echocardiography, there is a substantial risk of cardiac penetration during pericardiocentesis. Technical failure, pain, dysrhythmia, fever, infection, and cardiac arrest are described as complications of PPDS. Prolonged hospitalization is required for drainage of fluid and repeated sclerosant injections. Only 73% of effusions were controlled for Ͼ 30 days, 3 and median survival periods were only 98 days, 97 days, and 30 days in the series cited. These articles do not provide information on the success of this treatment in preventing recurrent pericardial effusion and tamponade beyond 30 days.
We have provided information documenting a very low rate of pericardial effusion recurrence following surgical window techniques, including thoracoscopic pericardial window, based on a careful standardized follow-up protocol including monthly clinical examination, chest roentgenograms, and/or echocardiograms. This information can be used as a historical control in future PPDS studies. Perhaps with increased experience and refinement of techniques, PPDS may achieve equivalent success with surgical window drainage. The best approach to resolve this question will be a prospective study of surgical window vs PPDS. 
